Literature DB >> 18955500

Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.

Stéphanie Solier1, Olivier Sordet, Kurt W Kohn, Yves Pommier.   

Abstract

TRAIL is an endogenous death receptor ligand also used therapeutically because of its selective proapoptotic activity in cancer cells. In the present study, we examined chromatin alterations induced by TRAIL and show that TRAIL induces a rapid activation of DNA damage response (DDR) pathways with histone H2AX, Chk2, ATM, and DNA-PK phosphorylations. Within 1 h of TRAIL exposure, immunofluorescence confocal microscopy revealed gamma-H2AX peripheral nuclear staining (gamma-H2AX ring) colocalizing with phosphorylated/activated Chk2, ATM, and DNA-PK inside heterochromatin regions. The marginal distribution of DDR proteins in early apoptotic cells is remarkably different from the focal staining seen after DNA damage. TRAIL-induced DDR was suppressed upon caspase inhibition or Bax inactivation, demonstrating that the DDR activated by TRAIL is downstream from the mitochondrial death pathway. H2AX phosphorylation was dependent on DNA-PK, while Chk2 phosphorylation was dependent on both ATM and DNA-PK. Downregulation of Chk2 decreased TRAIL-induced cell detachment; delayed the activation of caspases 2, 3, 8, and 9; and reduced TRAIL-induced cell killing. Together, our findings suggest that nuclear activation of Chk2 by TRAIL acts as a positive feedback loop involving the mitochondrion-dependent activation of caspases, independently of p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955500      PMCID: PMC2612481          DOI: 10.1128/MCB.00581-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  67 in total

1.  Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

Authors:  Ian Hickson; Yan Zhao; Caroline J Richardson; Sharon J Green; Niall M B Martin; Alisdair I Orr; Philip M Reaper; Stephen P Jackson; Nicola J Curtin; Graeme C M Smith
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

2.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

3.  Regulation of CHK2 by DNA-dependent protein kinase.

Authors:  Jia Li; David F Stern
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

4.  Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

Authors:  Rajani Ravi; Ajay J Jain; Richard D Schulick; Vui Pham; Traci S Prouser; Heather Allen; Elizabeth Garrett Mayer; Hua Yu; Drew M Pardoll; Avi Ashkenazi; Atul Bedi
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

5.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

Authors:  X Luo; I Budihardjo; H Zou; C Slaughter; X Wang
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

6.  Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM.

Authors:  Yuanlin Peng; Rick G Woods; Heather Beamish; Ruiqiong Ye; Susan P Lees-Miller; Martin F Lavin; Joel S Bedford
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

7.  Characterization of ATM expression, localization, and associated DNA-dependent protein kinase activity.

Authors:  D P Gately; J C Hittle; G K Chan; T J Yen
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

8.  Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells.

Authors:  J A Park; K W Kim; S I Kim; S K Lee
Journal:  Eur J Biochem       Date:  1998-10-01

9.  Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.

Authors:  Justin J J Leahy; Bernard T Golding; Roger J Griffin; Ian R Hardcastle; Caroline Richardson; Laurent Rigoreau; Graeme C M Smith
Journal:  Bioorg Med Chem Lett       Date:  2004-12-20       Impact factor: 2.823

10.  Megabase chromatin domains involved in DNA double-strand breaks in vivo.

Authors:  E P Rogakou; C Boon; C Redon; W M Bonner
Journal:  J Cell Biol       Date:  1999-09-06       Impact factor: 10.539

View more
  55 in total

1.  Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors.

Authors:  Stéphanie Solier; Jennifer Barb; Barry R Zeeberg; Sudhir Varma; Mike C Ryan; Kurt W Kohn; John N Weinstein; Peter J Munson; Yves Pommier
Journal:  Cancer Res       Date:  2010-09-03       Impact factor: 12.701

2.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

3.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression.

Authors:  Jing An; Yue-Cheng Huang; Qing-Zhi Xu; Li-Jun Zhou; Zeng-Fu Shang; Bo Huang; Yu Wang; Xiao-Dan Liu; De-Chang Wu; Ping-Kun Zhou
Journal:  BMC Mol Biol       Date:  2010-03-06       Impact factor: 2.946

Review 5.  Histone phosphorylation: a chromatin modification involved in diverse nuclear events.

Authors:  Dorine Rossetto; Nikita Avvakumov; Jacques Côté
Journal:  Epigenetics       Date:  2012-09-04       Impact factor: 4.528

Review 6.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

7.  ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

Authors:  Rozenn Jossé; Scott E Martin; Rajarshi Guha; Pinar Ormanoglu; Thomas D Pfister; Philip M Reaper; Christopher S Barnes; Julie Jones; Peter Charlton; John R Pollard; Joel Morris; James H Doroshow; Yves Pommier
Journal:  Cancer Res       Date:  2014-09-30       Impact factor: 12.701

8.  NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Authors:  Jenna H Burton; Christina Mazcko; Amy LeBlanc; Joseph M Covey; Jiuping Ji; Robert J Kinders; Ralph E Parchment; Chand Khanna; Melissa Paoloni; Sue Lana; Kristen Weishaar; Cheryl London; William Kisseberth; Erika Krick; David Vail; Michael Childress; Jeffrey N Bryan; Lisa Barber; E J Ehrhart; Michael Kent; Timothy Fan; Kelvin Kow; Nicole Northup; Heather Wilson-Robles; Joseph Tomaszewski; Julianne L Holleran; Miguel Muzzio; Julie Eiseman; Jan H Beumer; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

9.  Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.

Authors:  Won Ki Kim; Ju-Hwa Kim; Kyungsil Yoon; Sunshin Kim; Jungsil Ro; Han Sung Kang; Sungpil Yoon
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

10.  Phosphorylation of histone H2A.X as an early marker of neuronal endangerment following seizures in the adult rat brain.

Authors:  Samantha L Crowe; Susanna Tsukerman; Karen Gale; Timothy J Jorgensen; Alexei D Kondratyev
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.